Efficacy and Safety of Etrasimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by Baseline Modified Mayo Score: A Post Hoc Analysis From the Phase 3 ELEVATE UC Clinical Program

Authors

Remo Panaccione (ORCID: https://orcid.org/0000-0002-5247-940X)
John Woolcott (ORCID: https://orcid.org/0000-0001-7445-8696)
Bruce E. Sands (ORCID: https://orcid.org/0000-0001-5762-5042)
Severine A.R.A. Vermeire (ORCID: https://orcid.org/0000-0001-9942-3019)
Marla C. Dubinsky (ORCID: https://orcid.org/0000-0003-4968-5795)
Paulo Gustavo Kotze (ORCID: https://orcid.org/0000-0002-9632-6691)
Martina Goetsch
Andrés Yarur (ORCID: https://orcid.org/0000-0003-2293-5555)
Millie D. Long (ORCID: https://orcid.org/0000-0001-5983-2758)
Eustratios Bananis
Joseph Wu (ORCID: https://orcid.org/0009-0006-3464-2556)
Aoibhinn McDonnell (ORCID: https://orcid.org/0000-0002-2229-0382)

Institutions

University of North Carolina at Chapel Hill (US)
Cedars-Sinai Medical Center (US)
University of Calgary (CA)
Pontifícia Universidade Católica do Paraná (BR)
Pfizer (United States) (US)
Pfizer (United Kingdom) (GB)
Pfizer (Switzerland) (CH)
Icahn School of Medicine at Mount Sinai (US)
KU Leuven (BE)

Publication Details

Journal: Inflammatory Bowel Diseases
Published: 2025-02-10
DOI: https://doi.org/10.1093/ibd/izaf036
Citations: 3
Primary Topic: Inflammatory Bowel Disease
Type: article
Field-Weighted Citation Impact: 5.45

Funders

Pfizer

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Efficacy and Safety of Etrasimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by Baseline Modified Mayo Score: A Post Hoc Analysis From the Phase 3 ELEVATE UC Clinical Program

Remo Panaccione, John Woolcott, Bruce E. Sands, Severine A.R.A. Vermeire et al.

Feb 10, 2025

3 citations

Inflammatory Bowel Diseases

Inflammatory Bowel Disease

5.45

article

Efficacy and Safety of Etrasimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by Baseline Modified Mayo Score: A Post Hoc Analysis From the Phase 3 ELEVATE UC Clinical Program

Remo Panaccione, John Woolcott, Bruce E. Sands, Severine A.R.A. Vermeire, Marla C. Dubinsky, Paulo Gustavo Kotze, Martina Goetsch, Andrés Yarur, Millie D. Long, Eustratios Bananis, Joseph Wu, Aoibhinn McDonnell

February 10, 2025article en

3 citations

Abstract

No abstract available for this paper.

Inflammatory Bowel DiseasesVol. 31(10)

University of North Carolina at Chapel Hill (US), Cedars-Sinai Medical Center (US), University of Calgary (CA), Pontifícia Universidade Católica do Paraná (BR), Pfizer (United States) (US), Pfizer (United Kingdom) (GB), Pfizer (Switzerland) (CH), Icahn School of Medicine at Mount Sinai (US), KU Leuven (BE)

Pfizer

Good health and well-being

Openalex Percentile: Top 5%

Inflammatory Bowel Disease

5.45

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.